WO2010095879A2 - Petit arn interferent a lier a des transcrits de genes associes a l'apoptose et compositions de traitement du cancer contenant ce petit arni - Google Patents

Petit arn interferent a lier a des transcrits de genes associes a l'apoptose et compositions de traitement du cancer contenant ce petit arni Download PDF

Info

Publication number
WO2010095879A2
WO2010095879A2 PCT/KR2010/001031 KR2010001031W WO2010095879A2 WO 2010095879 A2 WO2010095879 A2 WO 2010095879A2 KR 2010001031 W KR2010001031 W KR 2010001031W WO 2010095879 A2 WO2010095879 A2 WO 2010095879A2
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
cancer
seq
tab2
traf7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/001031
Other languages
English (en)
Korean (ko)
Other versions
WO2010095879A3 (fr
Inventor
한보람
김성열
박한오
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneer Corp
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Publication of WO2010095879A2 publication Critical patent/WO2010095879A2/fr
Publication of WO2010095879A3 publication Critical patent/WO2010095879A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Definitions

  • RNAi RNAi-binding protein
  • the present invention provides an siRNA wherein the mRNA is transcribed from a tumor necrosis factor receptor associated factor (TRAF7) gene or a TAB1 binding protein 2 (TAB2) gene.
  • TRF7 tumor necrosis factor receptor associated factor
  • TAB2 TAB1 binding protein 2
  • the present invention provides a method for inhibiting tumor cells, comprising treating a cell with a solution containing at least one siRNA selected from the group consisting of the nucleotide sequences shown in SEQ ID NOs: 1-12.
  • siRNAs having the modified nucleotide sequence as follows were also identified. In addition, it was confirmed that it can still suppress the expression of TRAF7 mRNA.
  • the siRNA variants of SEQ ID NOS: 7-9 (sample names TRAF7-2449-M1, TRAF7-2449-M2, TRAF7-2449-M3, respectively) all replaced some bases in SEQ ID NO: 3 siRNA, as shown below.
  • the siRNA of the present invention can be used as a cancer-specific anticancer agent because it did not induce apoptosis in normal cells but not tumor cells.
  • the dosage of siRNA capable of complementarily binding to the mRNA encoding TRAF7 or TAB2 of the present invention is parenteral administration of 0.05 to 0.1 ⁇ g / kg body weight, depending on the patient's age, sex, symptoms, method of administration or prophylactic purpose. can do.
  • the level of dosage for a patient with specific symptoms can vary by the person skilled in the art depending on the weight, age, sex, health condition, diet, time of administration, method of administration, and the like of the patient.
  • a siRNA that inhibits the expression of TRAF7 or TAB2 of the present invention and a composition for treating cancer using the siRNA as an active ingredient can effectively inhibit tumor cell proliferation by inducing apoptosis of tumor cells and thus anticancer therapy for various uses. It can be widely used in.
  • 1 is a graph showing mRNA levels of TRAF7 expressed in cell lines 24 hours after transfection with three sequences of siRNA for TRAF7 of the present invention, wherein NC is transfected with negative control siRNA (negative control siRNA) Means control group.
  • Figure 2 is a graph showing the mRNA level of TRAF7 expressed over time after transfection with the SEQ ID NO: 2,3 siRNA of the present invention.
  • FIG. 3 is a graph showing the mRNA levels of TAB2 expressed in cell lines transfected with three sequences of siRNA for TAB2 of the present invention.
  • Figure 4 is a graph showing the mRNA level of TAB2 expressed over time after transfection with the SEQ ID NO: 4, 5 siRNA of the present invention.
  • FIG. 5 is a graph showing the mRNA level of TAB2 expressed after transfection with siRNA of SEQ ID NO: 4 and the prior art siRNA of the present invention.
  • TAB2-1301 siRNA of the present invention (SEQ ID NO: 4)
  • MCF7 human breast cancer cell lines
  • HeLa human cervical cancer cell lines
  • FIG. 8 is a diagram illustrating lung cancer cell line (A549) and human articular synovial cell (synoviocyte), which are normal cells, were transfected with siRNA to compare whether siRNA SEQ IDs 3 and 4 induce apoptosis. It is a photograph observing whether death was induced.
  • FIG. 12 is a photograph showing the induction of apoptosis in a cell line transfected with three variant siRNAs to the SEQ ID NO: 3 siRNA of the present invention. * Indicates a substituted portion of the sequence.
  • SEQID 3 siRNA of the present invention affects the growth of tumors.
  • FIG. 16 compares tumor formation patterns of rats and controls treated with human oral cancer cell lines (KB) transfected with SEQID 3 siRNA after 14, 20, 30, and 43 days of cancer cell line administration. One picture.
  • Opti-MEM Opti-MEM medium
  • RPMI1640 culture medium or DMEM culture medium or 2.5 ml of EMEM was dispensed and then cultured at 37 ° C. and 5% (v / v) CO 2 for 24 and 72 hours, respectively.
  • the level of mRNA of TAB2 present in the cell lines transfected with three siRNA was 5.5% of the control group (SEQ ID NO: 4), 12.1% of the control group (SEQ ID NO: 5), 14.3% of the control group (SEQ ID NO: 6) I could confirm that.
  • the siRNA of SEQ ID NO: 4 showed 5.5% of the control group, and it was found that the expression of TAB2 was most effectively suppressed (FIG. 3).
  • mRNA amount was compared 72 hours after transfection. As a result, it was found that even after 72 hours, expression of TAB2 was effectively inhibited by siRNA (FIG. 4).
  • human uterine cancer cell line HeLa was transfected using the same method as in Example 2-2 to analyze the effect of apoptosis according to the concentration.
  • Modified TRAF7 2449-M1 (SEQ ID NO: 7), 2449-M2 (SEQ ID NO: 8), 2449-M3 (SEQ ID NO: 3) partially modified with the nucleotide sequence of siRNA (SEQ ID NO: 3), which showed excellent effects in Example 2-3. 9) were produced respectively.
  • the Ct values of the obtained TAB2 and GAPDH were measured, respectively, and the ⁇ Ct value, which is the difference between the two values, was obtained, and then the control group transfected with negative control siRNA (NC-siRNA, BIONEER, Korea)
  • the value of ⁇ Ct which is the difference between the values of ⁇ Ct and ⁇ Ct was determined. From this value, the value of 2 (- ⁇ Ct) X 100 was obtained, and the reduction rate of mRNA expression of TAB2 was compared.
  • Tumor cells were injected into nude mice to induce tumor formation and confirmed the tumor growth inhibition effect of TRAF7 siRNA in vivo.
  • Tumor cells transfected in Example 3-1 were injected subcutaneously with 3 ⁇ 10 6 cells per head in Balb / c nude mice (5 weeks old, CB, Korea), and then the size of the formed tumor was fixed. It was analyzed whether the siRNA of SEQ ID NO: 3 affects tumor formation inhibition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un petit ARNi à lier à des transcrits de gènes associés à l'apoptose, ainsi que des compositions de traitement du cancer contenant ce petit ARNi. L'invention concerne plus particulièrement un petit ARNi qui se lie à l'ARNm de gènes du TRAF7 (facteur associé au récepteur du facteur de nécrose tumorale) ou de gènes de la TAB2 (protéine de liaison 2 à TAK1) pour inhiber l'expression de ces gènes, ce qui induit l'apoptose spécifique des cellules cancéreuses, ainsi que des compositions thérapeutiques contenant ce petit ARNi comme principe actif. Le petit ARNi et les compositions le contenant induisent l'apoptose spécifique des cellules cancéreuses et peuvent donc servir d'agents thérapeutiques anticancéreux efficaces qui n'endommagent pas les cellules saines.
PCT/KR2010/001031 2009-02-20 2010-02-19 Petit arn interferent a lier a des transcrits de genes associes a l'apoptose et compositions de traitement du cancer contenant ce petit arni Ceased WO2010095879A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090014369A KR20100095206A (ko) 2009-02-20 2009-02-20 세포사멸 관련 유전자의 전사체에 결합하는 ｓｉＲＮＡ 및 이를 이용한 암 치료용 조성물
KR10-2009-0014369 2009-02-20

Publications (2)

Publication Number Publication Date
WO2010095879A2 true WO2010095879A2 (fr) 2010-08-26
WO2010095879A3 WO2010095879A3 (fr) 2011-02-24

Family

ID=42634338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001031 Ceased WO2010095879A2 (fr) 2009-02-20 2010-02-19 Petit arn interferent a lier a des transcrits de genes associes a l'apoptose et compositions de traitement du cancer contenant ce petit arni

Country Status (2)

Country Link
KR (1) KR20100095206A (fr)
WO (1) WO2010095879A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114941010A (zh) * 2022-05-26 2022-08-26 华南农业大学 Tab2在猪卵巢颗粒细胞中的应用
CN114940992A (zh) * 2022-05-26 2022-08-26 华南农业大学 lncRNA TAB2-AS调控TAB2在猪卵巢颗粒细胞中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986599A1 (fr) 2013-04-17 2016-02-24 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526022A (ja) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法
KR100856108B1 (ko) * 2007-02-28 2008-09-02 한국생명공학연구원 Ｚｆｐ91의 활성을 조절하는 분자를 함유하는 항암제,항염증제, 면역질환치료제 또는 허혈성 질환 치료제

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114941010A (zh) * 2022-05-26 2022-08-26 华南农业大学 Tab2在猪卵巢颗粒细胞中的应用
CN114940992A (zh) * 2022-05-26 2022-08-26 华南农业大学 lncRNA TAB2-AS调控TAB2在猪卵巢颗粒细胞中的应用
CN114941010B (zh) * 2022-05-26 2023-08-15 华南农业大学 Tab2在猪卵巢颗粒细胞中的应用
CN114940992B (zh) * 2022-05-26 2023-08-29 华南农业大学 lncRNA TAB2-AS调控TAB2在猪卵巢颗粒细胞中的应用

Also Published As

Publication number Publication date
WO2010095879A3 (fr) 2011-02-24
KR20100095206A (ko) 2010-08-30

Similar Documents

Publication Publication Date Title
JP6033527B2 (ja) 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的
JP2022532169A (ja) オリゴヌクレオチド組成物及びその使用方法
JP2022550915A (ja) オリゴヌクレオチド組成物及びその使用方法
CN103333890B (zh) 治疗乙型病毒性肝炎的rna干扰制剂
US8927515B2 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
AU2020260479A1 (en) Methods and Compositions for the Specific Inhibition of Alpha-1 Antitrypsin by Double-Stranded RNA
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
JP2015211680A (ja) 遺伝子発現の阻害のためのショートヘアピンｒｎａ
EP2462936A1 (fr) Silençage post-transcriptionelle de gènes impliqués dans l'alopécie à médiation de petit ARN interférent
WO2018155890A1 (fr) Petit arni asymétrique permettant d'inhiber l'expression d'un gène cible de perte de cheveux masculine
JP2021511029A (ja) Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
AU2011256978A1 (en) siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2011122889A2 (fr) Procédé d'inhibition de la sénescence de cellules souches adultes en inhibant l'expression de miarn
WO2013125878A1 (fr) Régulation de la différenciation en neurones dopaminergiques par des métalloprotéases
WO2010095879A2 (fr) Petit arn interferent a lier a des transcrits de genes associes a l'apoptose et compositions de traitement du cancer contenant ce petit arni
WO2023027267A1 (fr) Oligonucléotide antisens possédant une activité d'inhibition de la régulation de la traduction de sars-cov-2 pour son utilisation dans la thérapie contre la maladie à coronavirus-19
CN114729363A (zh) Il-34反义剂及其使用方法
WO2018231034A2 (fr) Composition pharmaceutique pour prévenir ou traiter le cancer
KR20130014840A (ko) ｍｉＲ-636을 이용한 간암 치료 및 진단 방법
WO2011087343A2 (fr) Composition destinée à traiter un cancer lié à une infection par un papillomavirus humain
WO2020122534A1 (fr) Arnsi asymétrique pour inhiber l'expression de snai1
US20210017497A1 (en) Compositions and methods for cellular reprogramming
WO2015056970A1 (fr) Composition pour la prévention ou le traitement de l'ostéoporose, contenant un inhibiteur de progranuline comme principe actif
KR100694804B1 (ko) 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
EP4400110A1 (fr) Inhibiteur de la progression de l'arthrose et kit d'inhibition de la progression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10743954

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10743954

Country of ref document: EP

Kind code of ref document: A2